GYNE-LOTRIMIN COMBINATION PACK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GYNE-LOTRIMIN COMBINATION PACK (GYNE-LOTRIMIN COMBINATION PACK).
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity. Betamethasone, a corticosteroid, suppresses inflammatory responses via glucocorticoid receptor activation.
| Metabolism | Clotrimazole is primarily metabolized in the liver to inactive metabolites. Betamethasone is hepatically metabolized, primarily by CYP3A4. |
| Excretion | Clotrimazole: primarily fecal (biliary) as metabolites, <0.5% unchanged in urine. Betamethasone dipropionate: renal (primarily as inactive metabolites) and biliary/fecal. |
| Half-life | Clotrimazole: 3.5–6 hours (terminal). Betamethasone: 5.6 hours (terminal). Clinical context: Supports twice-daily dosing for antifungal effect; betamethasone systemic exposure minimal with vaginal use. |
| Protein binding | Clotrimazole: 90–95% (albumin, alpha-1-acid glycoprotein). Betamethasone: 64% (albumin). |
| Volume of Distribution | Clotrimazole: ~100 L (not weight-normalized; extensive tissue distribution). Betamethasone: 1.4 L/kg (suggests wide distribution, including CNS and placenta). |
| Bioavailability | Clotrimazole: negligible (<1%) systemic absorption via vaginal mucosa; 3–10% via topical skin. Betamethasone: minimal systemic absorption from vagina; ~12–14% from topical skin (intact), higher if damaged. |
| Onset of Action | Clotrimazole (vaginal): symptom relief within 1–3 days. Betamethasone (topical): anti-inflammatory effect within hours of application. |
| Duration of Action | Clotrimazole: clinical cure typically within 7 days; one-time 500 mg vaginal tablet provides therapeutic levels for ~3 days. Betamethasone: duration of anti-inflammatory effect 6–12 hours after single application. |
Intravaginal: One 500 mg vaginal tablet inserted at bedtime as a single dose; external: Apply clotrimazole 1% cream twice daily for 7 days.
| Dosage form | CREAM, TABLET |
| Renal impairment | No dosage adjustment required for renal impairment. Use with caution in severe renal disease. |
| Liver impairment | No dosage adjustment required for hepatic impairment. Use with caution in severe hepatic disease. |
| Pediatric use | Safety and efficacy in children <12 years not established. For adolescents ≥12 years: same as adult dosing. |
| Geriatric use | No specific geriatric dose adjustment required. Use same as adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GYNE-LOTRIMIN COMBINATION PACK (GYNE-LOTRIMIN COMBINATION PACK).
| Breastfeeding | Clotrimazole is poorly absorbed systemically, and transfer into breast milk is negligible. The M/P ratio is unknown but expected to be very low due to minimal systemic absorption. It is compatible with breastfeeding when used vaginally. |
| Teratogenic Risk | Clotrimazole is FDA Pregnancy Category B. Animal studies have not revealed evidence of teratogenicity. Use during all trimesters is considered safe, as systemic absorption is minimal (<0.5%) after intravaginal application. No increased risk of fetal malformations has been observed in human studies. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to clotrimazole, betamethasone, or any component.","Viral infections (e.g., herpes simplex, vaccinia, varicella) at treatment site."]
| Precautions | ["For intravaginal use only; not for ophthalmic or oral use.","Do not use if allergic to any component.","Discontinue if irritation or sensitization occurs.","Prolonged use may increase risk of secondary infections."] |
Loading safety data…
| Fetal Monitoring | No specific monitoring is required beyond standard prenatal care. However, if treatment is prolonged (e.g., >7 days) or recurrent infections occur, consider checking liver function tests due to rare hepatic effects. |
| Fertility Effects | No known adverse effects on fertility. Clotrimazole does not affect hormonal contraception efficacy. Standard topical use is not associated with impaired fertility in animal studies. |